Preliminary data from a phase III trial suggest nivolumab achieves better response rates and longer response durations than standard chemotherapy in patients with unresectable metastatic melanoma. The drug has a lower toxicity profile compared to chemotherapy, promoting a sustained immune response.
The IMPRESS trial found that continued gefitinib therapy after resistance development in lung cancer did not improve progression-free survival. Chemotherapy alone remains the standard treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Adding cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival for patients with relapsed or metastatic cervical cancer. The study, published in Annals of Oncology, shows greater tumour shrinkage and increased median progression-free survival compared to chemotherapy alone.
A phase III trial showed that Rolapitant significantly reduced nausea and vomiting in patients receiving cisplatin-based chemotherapy. The study found that 72.7% of patients experienced complete response, with improved quality of life outcomes.
Children exposed to chemotherapy or radiotherapy in utero suffer no negative impacts on mental or cardiac development, according to international studies presented at ESMO 2014. These findings confirm that chemotherapy and radiotherapy during pregnancy do not endanger the fetus and its subsequent development.
A recent study published in PNAS reveals the link between gelsolin protein and ovarian cancer resistance, providing a promising avenue for developing new therapies. By cutting down gelsolin levels, researchers found that chemo-resistant cells become susceptible to chemotherapy.
A study from the University of Pennsylvania found that combining exercise with chemotherapy shrunk tumors more than chemotherapy alone in a mouse model of melanoma. Exercise increased blood flow to the tumor, bringing more of the drug into the bloodstream, and may help reduce side effects.
A study found that combining chemotherapy and stereotactic ablative radiation (SABR) may be an effective treatment option for patients with locally advanced pancreatic cancer. After undergoing this treatment, nearly 90% of patients were able to undergo surgery, resulting in a high success rate.
Scientists have identified a novel gene that predicts both breast cancer relapse and response to chemotherapy, enabling doctors to classify patients for more effective treatment. The discovery could help reduce metastasis and increase the effectiveness of chemotherapy.
Chloroquine has been shown to inhibit tumor growth and metastases by normalizing abnormal blood vessels in tumors. This results in an increased barrier function blocking cancer cell dissemination and enhanced tumor perfusion increasing the response of the tumor to chemotherapy.
A Kaiser Permanente study found that older adults vaccinated against shingles are 42% less likely to develop the disease after undergoing chemotherapy. The vaccine also prevented hospitalizations for shingles among vaccinated patients, highlighting its importance in preventing long-term complications.
A new study reveals that adipose-derived human stem cells can withstand high doses of the chemotherapy drug methotrexate, unlike other cell types. This finding has significant implications for developing an ASC-based therapy to promote bone growth and regeneration in cancer patients.
Saint Louis University researchers have discovered a molecular pathway that causes painful chemotherapy side effects and found a potential way to block it. A drug already approved for treating multiple sclerosis may also alleviate chemotherapy-induced peripheral neuropathy (CIPN) without affecting the medication's anticancer properties.
Researchers found that fasting can replenish stem cells in the blood, combating chemotherapy-induced and aging-related changes in immune cell function. Fasting has also been shown to rejuvenate the immune system of old mice and protect against white blood cell loss in human patients.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS) found a significant benefit. Patients treated with adjuvant chemotherapy had an improved median overall survival, with a 23% increase compared to those not treated.
Researchers at Fox Chase Cancer Center halted a trial after 23% of patients experienced severe cardiovascular events while receiving a chemotherapy regimen. The study aimed to investigate the effectiveness and safety of gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
Researchers at Fox Chase Cancer Center found that genetic mutations in three specific genes can predict which bladder cancer patients will benefit from early chemotherapy. Patients with these mutations are more likely to respond to treatment and have a higher chance of being cancer-free after surgery.
A new clinical trial found that adding goserelin to chemotherapy regimens for premenopausal women with early-stage breast cancer significantly reduced the risk of early menopause. The study also showed improved overall survival rates and a higher pregnancy rate in the goserelin group.
An analysis by Fox Chase Cancer Center has revealed a dramatic increase in the use of chemotherapy before surgery to remove ovarian cancer, with 26.72% of patients receiving it in 2011 compared to 8.94% in 1998.
Researchers used large population-based data to compare six common chemotherapy regimens, identifying those with the highest risk of hospitalization. The study found that TAC and AC+T were associated with high hospitalization rates in younger patients, while all regimens except ddAC+P had higher risks for older patients.
A new chemotherapy regimen administered before surgery and chemoradiation improves tolerance to treatment in most rectal cancer patients. The study found that over 90% of patients were able to complete a full course of standard treatment, with many experiencing a significant reduction in symptoms.
Researchers at Children's Hospital Los Angeles have discovered a novel target, B-cell activating receptor (BAFF-R), for chemotherapy-resistant leukemia cells. By targeting this receptor, the team was able to selectively kill cancer cells in mouse models and increase killing of leukemia cells by natural killer cells and macrophages.
A new study from the University of Michigan Comprehensive Cancer Center found that nearly one-third of working women who had breast cancer were unemployed four years later. Women who received chemotherapy were most affected, with a significant increase in unemployment over time.
A gene expression profiling test analyzes patterns of 21 genes to predict cancer recurrence and benefit from chemotherapy. Many patients misunderstand the test's meaning, viewing it as a personalized and emotionally significant result rather than population-based statistics.
A study found that many women with early-stage breast cancer lose paid employment after diagnosis, particularly those who received chemotherapy. Women who received chemotherapy were 1.4 times more likely to be unemployed at follow-up.
Researchers at King's College London have identified new pain relief targets that could help chemotherapy patients who suffer from persistent pain. The discovery was made by investigating how pain occurs in nerves and found that the immune system plays a key role in causing pain.
Clinical trials show chemotherapy before surgery improves muscle-invasive bladder cancer survival. Chemotherapy after surgery also increases survival rates, with a significant improvement over time.
Researchers at the University of Southampton found that a combination of cetuximab and chemotherapy was not effective in treating advanced bowel cancer that had spread to the liver. The study, published in The Lancet Oncology, suggests that this treatment approach may even accelerate cancer progression in some cases.
A meta-analysis of randomized controlled trials found that chemotherapy improved progression-free survival compared to epidermal growth factor receptor tyrosine kinase inhibitors in patients with wild-type EGFR tumors. However, overall survival did not differ between the two groups.
Researchers measured p16 levels before, after and a year after chemotherapy to determine its impact on molecular aging. The study found that curative chemotherapy increased molecular age by an equivalent of 15 years in breast cancer patients. This suggests the p16 test may help evaluate treatment effects on long-term health and survival.
A new study found that adjuvant chemotherapy increases markers of molecular aging in the blood of BC survivors, including p16INK4a and ARF expression. These age-promoting effects may last for several years after treatment and even be permanent.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
Researchers found that CT scans can predict chemotherapy effectiveness by analyzing tumor density and contrast uptake. This breakthrough could lead to personalized treatment plans for patients with pancreatic cancer.
Research suggests that terminally ill cancer patients who receive chemotherapy in the last months of life are more likely to undergo intensive medical care and die in an intensive care unit. The study highlights the importance of end-of-life discussions between patients and physicians.
Research suggests that palliative chemotherapy can lead to more invasive medical procedures and a higher risk of death in intensive care units among advanced cancer patients. The findings highlight the need for clearer discussion of the harms and benefits of palliative chemotherapy at the end of life.
A multi-site research project led by Dr. Bradley J. Monk found that women with advanced cervical cancer live an average of 17 months longer when combined with bevacizumab and chemotherapy compared to chemotherapy alone. The study reveals a significant improvement in treatment outcomes for patients with metastatic cervical cancer.
Researchers discovered a new drug, spironolactone, that inhibits DNA repair mechanisms, making cancer cells more susceptible to chemotherapy. This finding has the potential to enhance cancer treatment protocols and improve patient outcomes.
Researchers at the University of Adelaide found that grape seed extract improves chemotherapy's potency and reduces intestinal damage in laboratory studies. Grape seed extracts showed no side effects on healthy intestine, decreased inflammation by up to 55%, and increased growth-inhibitory effects on colon cancer cells.
A 10.4-year median follow-up study by EORTC trial 22921 found that adjuvant chemotherapy does not improve survival or disease-free survival for cT3-resectable T4 M0 rectal cancer patients, highlighting the need for new treatment strategies.
A new study from the University of Michigan Comprehensive Cancer Center found that surgery significantly improves survival rates and functional outcomes for patients with advanced oral cavity cancer. In contrast, those who received chemotherapy after initial treatment had poorer results.
A nationwide study found that adding carboplatin to standard chemotherapy significantly increased tumor shrinkage in patients with triple-negative breast cancer. The results suggest that carboplatin could be used as an alternative or addition to current treatments.
A phase III clinical trial found that switching to a different chemotherapy did not improve overall survival or time to progression for women with metastatic breast cancer and elevated circulating tumor cells. Patients with low CTCs before starting chemotherapy had a median overall survival of 35 months, while those with elevated CTCs ...
A new trial found that adding chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved pathologic complete response rates for patients with triple-negative breast cancer. The study's adaptive design showed a 92% predictive probability of success in a phase III trial.
A randomized, phase II clinical trial found that adding carboplatin and/or bevacizumab to standard presurgery chemotherapy increased the number of patients with no residual cancer detected at surgery. The study showed significant increases in pathologic complete response rates for patients treated with these combinations.
Researchers at Dana-Farber Cancer Institute found a combination chemotherapy and targeted therapy reduced cancer recurrence in women with small, HER2-positive tumors. After 3.6 years, only 0.5% of patients experienced cancer recurrence.
A study led by Beth Israel Deaconess Medical Center researchers found that carbon monoxide can prevent tumor growth and amplify chemotherapy's effects, sparing healthy tissue. The findings suggest CO induces an 'anti-Warburg' effect, fueling cancer cell bioenergetics until metabolic exhaustion.
The EORTC trial found that perioperative chemotherapy with FOLFOX4 increases progression-free survival compared to surgery alone, but no significant difference in overall survival was observed. The study concludes that perioperative chemotherapy should remain the reference treatment for patients with resectable liver metastases from co...
Researchers at CWRU aim to build nanoparticles that can infiltrate and quash aggressive cancers that survive traditional therapy. They will perfect molecular coatings called ligands to enable nanochains to home in on micrometastases.
The EORTC/GIMEMA 06012 trial found sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy has no benefit for older patients with acute myeloid leukemia. GO is too toxic for patients over 70 years old, whereas younger patients may potentially benefit from such treatment.
A new study found that targeted treatment and conventional chemotherapy can be effective in treating ovarian cancer, particularly in women with BRCA gene mutations. The treatment combination showed promising results in patients who had previously developed resistance to PARP inhibitor drugs.
A Mayo Clinic-led study found that a less-invasive procedure called sentinel lymph node surgery successfully identified whether cancer remained in lymph nodes in 91% of patients with node-positive breast cancer who received chemotherapy before their surgery. The procedure removed only a few lymph nodes, reducing surgical complications.
A clinical trial found that cediranib, a biological therapy, extended the time before ovarian cancer recurred and increased overall survival by up to 30% compared to chemotherapy alone. The treatment showed incremental improvements in progression-free and overall survival.
A recent retrospective study found that chemotherapy improves median survival among elderly patients with small cell lung cancer (SCLC) by more than 6 months. The study analyzed data from 10,428 patients aged 65 and older who received chemotherapy between 1992 and 2001.
A phase I clinical trial shows that diffuse, large B-cell lymphomas resistant to chemotherapy can be reprogrammed to respond using the drug azacitidine. Patients whose tumors do not respond to standard therapies are being treated with a combination of approaches, including high-dose chemotherapy and stem cell transplant.
Researchers found that giving chemotherapy drug carboplatin before radiotherapy could reduce relapse rates and allow radiation doses to be lowered in men with stage IIA and IIB testicular seminoma. The study showed improved treatment outcomes and reduced long-term side effects.
A study suggests blocking part of a DNA repair complex can increase chemotherapy effectiveness and enhance survival in therapy-resistant leukemia. Researchers found that combining mTOR inhibitors with chemotherapy was far more effective at treating T-cell acute lymphoblastic leukemia (T-ALL) than standalone treatments.
Researchers discovered a biological mechanism that preserves intestinal tracts in mice treated with lethal doses of chemotherapy, increasing survival rates by up to 75%. The findings could revolutionize cancer therapy by allowing humans to tolerate stronger doses of chemotherapy and radiation, potentially curing later-stage metastasize...
Recent studies have found chemotherapy-associated adverse neurological effects, including vascular complications and neuropathic pains. Chemotherapy triggers changes in ion channels on dorsal root ganglia, resulting in secondary changes that affect neurogenesis and plasticity.
A phase III trial found that adding chemotherapy to surgery after curative D2 gastrectomy improved 5-year survival by 34% compared to surgery alone. The study, CLASSIC, added combination chemotherapy (XELOX) to standard treatment, showing a significant reduction in cancer-related death.